Eli Lilly's Stock Surge: Is a Split Next?
Business & Finance News Today | 2 Min News | The Daily News Now! · The Daily News Now!
Audio is streamed directly from the publisher (api.fastcast.ai) as published in their RSS feed. Play Podcasts does not host this file. Rights-holders can request removal through the copyright & takedown page.
Show Notes
Eli Lillys stock, currently around $900, is generating buzz for a potential split, signaling confidence in future growth. Their obesity drugs, Mounjaro and Zepbound, saw massive gains, with Mounjaro revenue surging 99% to $23 billion and Zepbound soaring 175% to $13.5 billion. Total revenue hit $65.2 billion, up 45%, and earnings per share climbed 86% to $24.2. With a huge untapped market, Lilly is investing heavily in new factories and trials. Forecasting $80-83 billion in revenue next year, driven by patient demand, an oral version could attract more users. Wall Street hints at a split as early as 2026, keeping Lilly in the growth spotlight.
Support the show:
Get a discount at https://solipillow.com/discount/dnn.
Advertise on DNN:
[email protected]
This is an automated, high-level news summary based on public reporting.
Report issues to [email protected].
View sources & latest updates:
https://sources.thednn.ai/a9e5dff8315326c0